본문 바로가기
KERD
논문KCI 등재

Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease

Jin Mo Yang|U Im Chang|Sang-Wook Song|Sung-Goo Kang|Do Seon Song
거트앤리버 소화기연관학회협의회|2019.11|Gut and Liver|제13권 제6호|pp. 658-668|DOI 10.5009/gnl18439

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Coronary artery calcium scoreNon-alcoholic fatty liver diseaseLiver fibrosis marker

초록

Background/Aims: Advanced hepatic fibrosis is associated with cardiovascular disease (CVD) in patients with nonalcoholic fatty liver disease (NAFLD). We investigated the association between noninvasive serum fibrosis markers and the coronary artery calcium score (CACS) in subjects with NAFLD. Methods: We analyzed 665 NAFLD subjects without chronic liver disease or heart disease between 2011 and 2015. The noninvasive fibrosis markers that were used to evaluate the severity of hepatic fibrosis included the NAFLD fibrosis score (NFS), fibrosis-4 (FIB-4) score, Forn’s index, and the aspartate aminotransferase to platelet ratio index (APRI). Results: The areas under the receiver operating characteristics curves for the NFS, FIB-4 score, Forn’s index and APRI for predicting CACS >100 were 0.689, 0.683, 0.659, and 0.595, respectively. According to the multivariate analysis, older age, increased body mass index (BMI), and decreased estimated glomerular filtration rate (eGFR) were significant factors associated with CACS >100. The NFS, FIB-4 score and APRI were significantly associated with CACS >100 after adjusting for age and gender (p=0.006, p=0.012, and p=0.012, respectively) and after adjusting for age, gender, BMI and eGFR (p=0.013, p=0.022, and p=0.027, respectively). Scores integrating noninvasive fibrosis markers and other risk factors improved the predictive accuracy. Conclusions: The NFS and FIB-4 score were associated with coronary atherosclerosis in subjects with NAFLD. Furthermore, scores integrating these noninvasive scores and risk factors for CVD showed good discriminatory power in predicting CACS >100. Therefore, noninvasive serum fibrosis markers may be useful tools for identifying NAFLD subjects at a high risk for CVD.

Abstract

Background/Aims: Advanced hepatic fibrosis is associated with cardiovascular disease (CVD) in patients with nonalcoholic fatty liver disease (NAFLD). We investigated the association between noninvasive serum fibrosis markers and the coronary artery calcium score (CACS) in subjects with NAFLD. Methods: We analyzed 665 NAFLD subjects without chronic liver disease or heart disease between 2011 and 2015. The noninvasive fibrosis markers that were used to evaluate the severity of hepatic fibrosis included the NAFLD fibrosis score (NFS), fibrosis-4 (FIB-4) score, Forn’s index, and the aspartate aminotransferase to platelet ratio index (APRI). Results: The areas under the receiver operating characteristics curves for the NFS, FIB-4 score, Forn’s index and APRI for predicting CACS >100 were 0.689, 0.683, 0.659, and 0.595, respectively. According to the multivariate analysis, older age, increased body mass index (BMI), and decreased estimated glomerular filtration rate (eGFR) were significant factors associated with CACS >100. The NFS, FIB-4 score and APRI were significantly associated with CACS >100 after adjusting for age and gender (p=0.006, p=0.012, and p=0.012, respectively) and after adjusting for age, gender, BMI and eGFR (p=0.013, p=0.022, and p=0.027, respectively). Scores integrating noninvasive fibrosis markers and other risk factors improved the predictive accuracy. Conclusions: The NFS and FIB-4 score were associated with coronary atherosclerosis in subjects with NAFLD. Furthermore, scores integrating these noninvasive scores and risk factors for CVD showed good discriminatory power in predicting CACS >100. Therefore, noninvasive serum fibrosis markers may be useful tools for identifying NAFLD subjects at a high risk for CVD.

참고문헌 (53)

  1. Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology", Gastroenterology, 142, pp.1592~1609 (2012)
  2. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  3. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
  4. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
  5. Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
  6. Wong RJ, "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States", Gastroenterology, 148, pp.547~555 (2015)
  7. Kim D, "Nonalcoholic fatty liver disease is associated with coronary artery calcification", Hepatology, 56, pp.605~613 (2012)
  8. Jaruvongvanich V, "Nonalcoholic fatty liver disease is associated with coronary artery calcification : a systematic review and meta-analysis", Dig Liver Dis, 48, pp.1410~1417 (2016)
  9. Targher G, "Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease", Diabetes Care, 29, pp.1325~1330 (2006)
  10. Ong JP, "Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease", J Hepatol, 49, pp.608~612 (2008)
  11. Patel K, "Diagnosis of liver fibrosis : present and future", Semin Liver Dis, 35, pp.166~183 (2015)
  12. European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines : non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
  13. Bedossa P, "Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease", Gastroenterology, 150, pp.1811~1822 (2016)
  14. Agatston AS, "Quantification of coronary artery calcium using ultrafast computed tomography", J Am Coll Cardiol, 15, pp.827~832 (1990)
  15. Hajar R, "Risk factors for coronary artery disease : historical perspectives", Heart Views, 18, pp.109~114 (2017)
  16. Levey AS, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group", Ann Intern Med, 130, pp.461~470 (1999)
  17. Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
  18. Bedogni G, "The Fatty Liver Index : a simple and accurate predictor of hepatic steatosis in the general population", BMC Gastroenterol, 6, pp.33~ (2006)
  19. Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
  20. Vallet-Pichard A, "FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
  21. Forn’ss X, "Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model", Hepatology, 36(4 Pt 1), pp.986~992 (2002)
  22. Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
  23. Kim NH, "Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population", Heart, 100, pp.938~943 (2014)
  24. Detrano R, "Coronary calcium as a predictor of coronary events in four racial or ethnic groups", N Engl J Med, 358, pp.1336~1345 (2008)
  25. Sinn DH, "Non-alcoholic fatty liver disease and progression of coronary artery calcium score : a retrospective cohort study", Gut, 66, pp.323~329 (2017)
  26. Sinn DH, "Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis", Gastroenterology, 151, pp.481~488 (2016)
  27. Polonsky TS, "Coronary artery calcium score and risk classification for coronary heart disease prediction", JAMA, 303, pp.1610~1616 (2010)
  28. Greenland P, "Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals", JAMA, 291, pp.210~215 (2004)
  29. Wilson PW, "Prediction of coronary heart disease using risk factor categories", Circulation, 97, pp.1837~1847 (1998)
  30. Sarnak MJ, "Kidney disease as a risk factor for development of cardiovascular disease : a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention", Hypertension, 42, pp.1050~1065 (2003)
  31. You SC, "Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification", J Gastroenterol Hepatol, 30, pp.1536~1542 (2015)
  32. Kim D, "Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States", Hepatology, 57, pp.1357~1365 (2013)
  33. Hannah WN Jr, "Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Hepatology, 64, pp.2234~2243 (2016)
  34. Kwok R, "Systematic review with metaanalysis:non-invasive assessment of non-alcoholic fatty liver disease. The role of transient elastography and plasma cytokeratin-18fragments", Aliment Pharmacol Ther, 39, pp.254~269 (2014)
  35. Castéra L, "Pitfalls of liver stiffness measurement : a 5-year prospective study of 13, 369 examinations", Hepatology, 51, pp.828~835 (2010)
  36. Wong GL, "Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population", J Gastroenterol Hepatol, 26, pp.300~305 (2011)
  37. Myers RP, "Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients", Hepatology, 55, pp.199~208 (2012)
  38. Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
  39. Gaia S, "Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis", J Hepatol, 54, pp.64~71 (2011)
  40. Imajo K, "Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography", Gastroenterology, 150, pp.626~637 (2016)
  41. Huwart L, "Magnetic resonance elastography for the noninvasive staging of liver fibrosis", Gastroenterology, 135, pp.32~40 (2008)
  42. Ichikawa S, "Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis", Magn Reson Imaging, 33, pp.26~30 (2015)
  43. Castera L, "Noninvasive evaluation of NAFLD", Nat Rev Gastroenterol Hepatol, 10, pp.666~675 (2013)
  44. Sinn DH, "Development of chronic kidney disease in patients with non-alcoholic fatty liver disease : a cohort study", J Hepatol, 67, pp.1274~1280 (2017)
  45. Ampuero J, "The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity", Aliment Pharmacol Ther, 48, pp.1260~1270 (2018)
  46. Kestenbaum BR, "Incidence and progression of coronary calcification in chronic kidney disease : the Multi-Ethnic Study of Atherosclerosis", Kidney Int, 76, pp.991~998 (2009)
  47. Tonelli M, "Risk of coronary events in people with chronic kidney disease compared with those with diabetes : a population-level cohort study", Lancet, 380, pp.807~814 (2012)
  48. Hwang IC, "Systemic Inflammation Is Associated With Coronary Artery Calcification and All-Cause Mortality in Chronic Kidney Disease", Circ J, 80, pp.1644~1652 (2016)
  49. Byrne CD, "NAFLD: a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
  50. Oh H, "Non-alcoholic fatty liver diseases : update on the challenge of diagnosis and treatment", Clin Mol Hepatol, 22, pp.327~335 (2016)
  51. Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
  52. Zhu Q, "Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis", J Renin Angiotensin Aldosterone Syst, 17, pp.1470320316628717~ (2016)
  53. Kamal S, "Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease : a systematic review and meta-analysis", Am J Gastroenterol, 112, pp.1495~1505 (2017)

관련 논문AI추천

Nonalcoholic Fatty Liver Disease Is Associated with the Presence and Morphology of Subclinical Coronary Atherosclerosis강민경, 강병훈, 김종호연세대학교의과대학 · Yonsei Medical Journal2015 · 제56권 제5호Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver DiseaseAhn Sang Hoon, Cha Bong-Soo, Han Eugene, Kang Eun Seok, Kim Beom Kyung, Kim Do Young, Kim Seung Up, Lee Byung-Wan, Lee Hye Won, Lee Jae Seung, Lee Yong-ho, Park Jun Yong거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제5호Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease강민규, 김민철, 박정길연세대학교의과대학 · Yonsei Medical Journal2020 · 제61권 제10호Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease김혜순, Ahn Sang Hoon, Cha Bong-Soo, Han Eugene, Kang Eun Seok, Kim Beom Kyung, Kim Do Young, Kim Mi Kyung, Kim Seung Up, Kim Yuna, Lee Byung-Wan, Lee Hye Won, Lee Jae Seung, Lee Yong-ho, Park Jun Yong거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제2호Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis안상봉, 이지은, Choi Miyoung, Cho Yuri, Han Sangsoo, Jun Dae Won, Kang Seong Hee, Lee Bora, Lee Hye Won, Song Do Seon, Yoo Jeong-Ju거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제6호Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver DiseasesHan Man-Hoon, Hur Keun, Jang Se Young, Kim Gyeonghwa, Kweon Young-Oh, Lee Won Kee, Lee Yu Rim, Park Soo Young, Tak Won Young대한진단검사의학회 · Annals of Laboratory Medicine2021 · 제41권 제3호

이 간행물의 다른 논문 (12건)

Prevalence of Helicobacter pylori Infection in Patients with Chronic Kidney DiseaseJi Yong Ahnpp. 585-586Genetic Analysis Can Surrogate the Treatment Strategies in Patients with Pancreatic CancerDong Uk Kimpp. 587-588New Biomarkers of Chronic Hepatitis BWai-Kay Seto, Lung-Yi Mak, James Fung, Man-Fung Yuenpp. 589-595Diagnosis and Management of Gastric Intestinal Metaplasia: Current Status and Future DirectionsMatthew M. Yeh, Joo Ha Hwang, Robert J. Huang, Alyssa Y. Choi, Camtu D. Truongpp. 596-603Perspectives on Current and Novel Treatments for Inflammatory Bowel DiseaseSoo-Young Na, Won Moonpp. 604-616
원문 보기